How to buy Black Diamond Therapeutics stock (BDTX)

Black Diamond Therapeutics is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.22 – a decrease of 13.28% over the previous week. Black Diamond Therapeutics employs 54 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Black Diamond Therapeutics stock

Buy Black Diamond Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Black Diamond Therapeutics stock price (NASDAQ: BDTX)

Use our graph to track the performance of BDTX stocks over time.

Black Diamond Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.22
52-week range	$2.22 - $7.66
50-day moving average more info button	$2.89
200-day moving average more info button	$4.67
Wall St. target price	$14.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.33

Is it a good time to buy Black Diamond Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Black Diamond Therapeutics price performance over time

Historical closes compared with the close of $2.22 from 2024-12-20

1 week (2024-12-13)	-13.28%
1 month (2024-11-22)	-12.60%
3 months (2024-09-20)	-53.36%
6 months (2024-06-21)	-54.13%

1 year (2023-12-22)	-22.65%
2 years (2022-12-22)	68.18%
3 years (2021-12-22)	5.44
5 years (2019-12-19)	N/A

Black Diamond Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-32.78%
Return on equity TTM	-63.09%
Profit margin	0%
Book value	$1.72
Market Capitalization more info button	$132.4 million

TTM: trailing 12 months

Black Diamond Therapeutics share dividends

We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.

Black Diamond Therapeutics share price volatility

Over the last 12 months, Black Diamond Therapeutics's shares have ranged in value from as little as $2.22 up to $7.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Black Diamond Therapeutics's is 2.518. This would suggest that Black Diamond Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Black Diamond Therapeutics overview

Black Diamond Therapeutics, Inc. , a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc.

Frequently asked questions

null
What percentage of Black Diamond Therapeutics is owned by insiders or institutions?
Currently 2.289% of Black Diamond Therapeutics shares are held by insiders and 98.712% by institutions. How many people work for Black Diamond Therapeutics?
Latest data suggests 54 work at Black Diamond Therapeutics. When does the fiscal year end for Black Diamond Therapeutics?
Black Diamond Therapeutics's fiscal year ends in December. Where is Black Diamond Therapeutics based?
Black Diamond Therapeutics's address is: One Main Street, Cambridge, MA, United States, 02142 What is Black Diamond Therapeutics's ISIN number?
Black Diamond Therapeutics's international securities identification number is: US09203E1055 What is Black Diamond Therapeutics's CUSIP number?
Black Diamond Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09203E105